| 摘要 |
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3.beta.-hydroxy- 17.beta.-aminoandrost-5-ene, 3.beta.-hydroxy-16.alpha.-fluoro-17.beta.- aminoandrost-5-ene, 3.alpha.-hydroxy-16.alpha.-fluoro-17.beta.-aminoandrost- 5- ene, 3.beta.-hydroxy-16.beta.-fluoro-17.beta.-aminoandrost-5-ene, 1.alpha.,3.beta.-dihydroxy-4.alpha.-fluoroandrost-5-ene-17-one, 1.alpha.,3.beta., 17.beta.-trihydroxy-4.alpha.-fluorandrost-5-ene, 1.beta.,3.beta.-dihydroxy-6.alpha.-bromoandrost-5-ene, 1.alpha.-fluoro- 3.beta.,12.alpha.-dihydroxyandrost-5-ene-17-one, 1.alpha.-fluoro- 3.beta.,4.alpha.-dihydroxyandrost-5-ene and 4.alpha.-fluoro-3.beta.,6.alpha. , 17.beta.-trihydroxyandrostante.
|
| 申请人 |
HOLLIS-EDEN PHARMACEUTICALS, INC. |
发明人 |
AUCI, DOMINICK L.;AHLEM, CLARENCE N.;READING, CHRISTOPHER;DOWDING, CHARLES;TRAUGER, RICHARD J.;PAGE, THEODORE M.;STICKNEY, DWIGHT R.;WHITE, STEVEN K.;FRINCKE, JAMES;LI, MEI |
